Home » Stocks » AVCO

Avalon GloboCare Corp. (AVCO)

Stock Price: $1.24 USD 0.06 (5.08%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 100.93M
Revenue (ttm) 1.40M
Net Income (ttm) -15.03M
Shares Out 80.62M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.24
Previous Close $1.18
Change ($) 0.06
Change (%) 5.08%
Day's Open 1.21
Day's Range 1.18 - 1.25
Day's Volume 568,680
52-Week Range 0.86 - 2.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

FREEHOLD, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, ...

GlobeNewsWire - 3 months ago

Assure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Assure/Fastep® COVID-19 Point-of-Care Antib...

GlobeNewsWire - 3 months ago

FREEHOLD, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a clinica...

GlobeNewsWire - 4 months ago

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutic...

GlobeNewsWire - 4 months ago

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutic...

GlobeNewsWire - 5 months ago

In anticipation of high demand, Avalon is working with Cellex to source manufacturing facilities and develop next generation COVID-19 testing kits In anticipation of high demand, Avalon is wor...

GlobeNewsWire - 5 months ago

FREEHOLD, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics...

GlobeNewsWire - 6 months ago

FREEHOLD, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced an upd...

GlobeNewsWire - 6 months ago

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

GlobeNewsWire - 6 months ago

- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a nove...

GlobeNewsWire - 7 months ago

FREEHOLD, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that t...

GlobeNewsWire - 7 months ago

FREEDHOLD, N.J., June 08, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based therapeutics and in vitro diagnostics, announced tod...

GlobeNewsWire - 8 months ago

FREEHOLD, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it...

GlobeNewsWire - 8 months ago

FREEHOLD, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that ...

GlobeNewsWire - 9 months ago

FREEHOLD, N.J., April 20, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that ...

GlobeNewsWire - 10 months ago

FREEHOLD, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that i...

GlobeNewsWire - 1 year ago

FREEHOLD, N.J., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has...

Seeking Alpha - 1 year ago

Avalon: Fortressing Capital Structure And Strengthening Fundamentals

GlobeNewsWire - 1 year ago

Company to Remain with Zero Warrants Outstanding Company to Remain with Zero Warrants Outstanding

Seeking Alpha - 1 year ago

Avalon's CAR-Ts are ahead of their time due to key advantages over conventional medicines. AVA-101 shuttles enough genes to decimate two oncology targets (CD19 and CD22).

GlobeNewsWire - 1 year ago

Unsecured credit facility carries 5% interest, all payments deferred for 36 months and is non-convertible into equity; Proceeds to be used to accelerate R&D, clinical studies and commercializa...

Seeking Alpha - 1 year ago

Avalon is gearing to hit a trifecta with three highly promising businesses, including exosome diagnostics, regenerative medicine, and cellular immunotherapy.

Other stocks mentioned: GE
Seeking Alpha - 1 year ago

Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.

About AVCO

Avalon GloboCare, together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. It also develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-ba... [Read more...]

Industry
Medical Care Facilities
CEO
Dr. David K. Jin
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
AVCO
Full Company Profile

Financial Performance

In 2019, AVCO's revenue was $1.55 million, a decrease of -1.02% compared to the previous year's $1.56 million. Losses were -$18.07 million, 132.4% more than in 2018.

Financial Statements